{"name":"CStone Pharmaceuticals","slug":"cstone-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CS1001 monoclonal antibody","genericName":"CS1001 monoclonal antibody","slug":"cs1001-monoclonal-antibody","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CS1001+ Fluorouracil+Cisplatin","genericName":"CS1001+ Fluorouracil+Cisplatin","slug":"cs1001-fluorouracil-cisplatin","indication":"Gastric or gastroesophageal junction cancer","status":"phase_3"},{"name":"Placebo+ Fluorouracil+Cisplatin","genericName":"Placebo+ Fluorouracil+Cisplatin","slug":"placebo-fluorouracil-cisplatin","indication":"Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline)","status":"phase_3"}]}],"pipeline":[{"name":"CS1001 monoclonal antibody","genericName":"CS1001 monoclonal antibody","slug":"cs1001-monoclonal-antibody","phase":"phase_3","mechanism":"CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"CS1001+ Fluorouracil+Cisplatin","genericName":"CS1001+ Fluorouracil+Cisplatin","slug":"cs1001-fluorouracil-cisplatin","phase":"phase_3","mechanism":"CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.","indications":["Gastric or gastroesophageal junction cancer","Esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Placebo+ Fluorouracil+Cisplatin","genericName":"Placebo+ Fluorouracil+Cisplatin","slug":"placebo-fluorouracil-cisplatin","phase":"phase_3","mechanism":"This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design.","indications":["Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9RdF9OOGpjbEpvanJJNjRVMUhRVHRBaE9jZmtoVTE2YlJ1TWhiaEoyTEU1anNZOEVzM0hmVnUtVXZfTFVQTks5U1FyTXVnUjhYaDBVMnBNM2NpTUs2ZlFQRGxWa0R4WjgwNHZjT3h0TEstUQ?oc=5","date":"2026-03-31","type":"pipeline","source":"AASTOCKS.com","summary":"Bearish block trade of CSTONE PHARMA-B(02616) 2.6M shares at $8.7, $22.62M turnover - AASTOCKS.com","headline":"Bearish block trade of CSTONE PHARMA-B(02616) 2.6M shares at $8.7, $22.62M turnover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPcmE5MjR3c25NVFlPS0NTOHZsZlB0cEtjOVU0dGJBS3lYVGQzLTlkYjI5ZHVLUTc5NmI4cXhzZ1lrdVhYMm5KTGRrZXExMWtXTmRyZ0pfa0VGMFJHN3lBbm5Db25aSy02NHBfTzl1cnJ3UnVWTmt5eXc1blAtRWJtZFBIa0xKYVR0Rnh4Q3hiLXJRbmpxTVRhQnoyYjJoQ0sxd2JKM2NHWm11YUkwejYwUG13dllQM1k?oc=5","date":"2026-03-29","type":"earnings","source":"Moomoo","summary":"Earnings Update: CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Are Trimming Their Forecasts - Moomoo","headline":"Earnings Update: CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Are Trimming Their Forecasts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPS1Z0bXBDUkcxejI3Q2szaWR2VGoyaGdSSDYwSnVfM0RHNC1nYzNRM2NwS0NJZnIyNUd3aE0wLVc0aVY2TkFXdDRSVVpVS2EzdDZEczNPSXh1b3RicEtiYnRjMmgxbEJkcGFLRzV3UF9DTy1vcnJhSFlCRWVuSEpqM1gta3h3TlM5bVc1N0dDQXVJNThMZ0c0RVRGMFByRFNoV1JjQTluMFdkZ09uTGJXSFVzZTBEVm1nN292QWZPdEttNFNYejREZA?oc=5","date":"2026-03-29","type":"pipeline","source":"Smartkarma","summary":"CStone Pharma (2616 HK): 2025 Seen Off Well, 2026 Would Be Crucial. A Possible Turnaround On Cards? - Smartkarma","headline":"CStone Pharma (2616 HK): 2025 Seen Off Well, 2026 Would Be Crucial. A Possible Turnaround On Cards?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"regulatory","source":"Indian Pharma Post","summary":"Veristat expands global trial & regulatory services as Chinese drugmakers push overseas - Indian Pharma Post","headline":"Veristat expands global trial & regulatory services as Chinese drugmakers push overseas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQRmdITkIzU1l0cTZ1VjZreGFMS19VLUxPOFdLLW9xeWdxMkIzaEg3VnJJSEk3SzBsSFNibUxSWTlpM1ZRcWthNllUT1d0OVBnd1lUUG85RkdUOWlrQWJIMHNyVElvVi1MUlNmczJNNUpZSV9QSlNQS3BCREVhYS1LS01nRUhESk9Ic0lLOGdkOHN2QjRHZlRESVdnbTdjbHdlTURz?oc=5","date":"2025-07-24","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNZkdCeFM2eDdpNTNYSWw3VWFwSUpxckJHYThDVVZncHVydWpuYlpvZ0RTZUQtZUZGUFNQc0wwUTZUMFdVM1R3Xy1aQ0E5ellyNjBDMFcxS004OGdNa0FoTnlWZl9NR0RmMk9kbHpmUUxtY2RENEFqMUl2V1QwbkZWSlpmRTdhMXJjNklteklnMmg0b0RubFVDWExjWQ?oc=5","date":"2025-07-10","type":"regulatory","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma","headline":"Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1RS3FnbUs3WS1YSFlLSnZYXzFxaFI4cWMwZmx4UE1mUVFyRWxEQXBzcjFaU3RHV1VpZ0tvM2hVakdQSTd1TG5wM3h1SEp2eGp2U3Nr?oc=5","date":"2025-05-19","type":"pipeline","source":"FirstWord Pharma","summary":"Pfizer pays $1.25B upfront for rights to PD-1/VEGF bispecific from China's 3SBio - FirstWord Pharma","headline":"Pfizer pays $1.25B upfront for rights to PD-1/VEGF bispecific from China's 3SBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQR2RVRzRFdXBDc0o3OW9sWERUQ3ZpYW5pUldjdW1vTmRpNjVSRGhsNU1CWjNmRXcxN2Y0TGVZc0g0TGlISE54WGlKRTdEQ0V6RGRHR2FDaFFwUzY0NmpVZnZYNHgyVHV0Ym9RRV94NDlCc0dMalJRZmpkUUxPQUdTbzFld2VqVGZoRVlxczlmc0ZPWVJUVlBMSDZCeklMZzdhUHJpQWNDZ0psZkh2MVNYNFNBLURram00Z29GQ09heldESElLaHprNlQ5ZktLTDFjWWZmYXRlRUk1YWVoVzRYQzl0NWJidVZFVGN3em9Udw?oc=5","date":"2025-03-06","type":"trial","source":"BioPharma APAC","summary":"CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment - BioPharma APAC","headline":"CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQVTlCWkItSHBaMWJpV3FoQldJWlB6TWFJMXZXQUI2bnhNTURQbjlITjNKZEVHOG1yM19hMnA4Z1NVWmRYamZtYnlMN3hVZTdCWUdMMVdUdUJSWlNrUnFQSzFwQ2c1RHJ4Mkh1c2lQem11YlpVRVZMUEFZNjZIakJLZWpnb3QwR2R0elNuYVZpX19GUm5VUlE?oc=5","date":"2025-01-28","type":"deal","source":"Pharmaceutical Executive","summary":"CStone and SteinCares Partner to Market and Commercialize Cancer Medication in Latin America - Pharmaceutical Executive","headline":"CStone and SteinCares Partner to Market and Commercialize Cancer Medication in Latin America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOckhsUnJyZEwtMnNVcmUwX3E2aC1vSkNRellfU3pMZHY2QVBDNFd0TVdINEFwVmpSejBrNlZHYVMzM3FRelE0YnhqU1FPMWxzcnQ2c1VpaDdPNG9BV0J5WEZMN0VZaktiVVl5Ty1vWll1ZjZLNVNGX2YwY2ZoMXZSeWt4bzFsWFgyd1Y1VVlac19lX1Bjb3hYWi1ISXgyUDc2S0xrTURLSGxEdDctcHBsVA?oc=5","date":"2024-11-04","type":"regulatory","source":"PMLiVE","summary":"MHRA approves CStone Pharmaceuticals’ sugemalimab to treat lung cancer in adults - PMLiVE","headline":"MHRA approves CStone Pharmaceuticals’ sugemalimab to treat lung cancer in adults","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdUJKc0k0VWVvQ25qT1lZQmxKbmRBSENrX2k2WTMta1dzci13TkRlZi12ZDlFTzNXd18tRWdiLWZkWk1aWlNVdUx0Y2lTZjFvd1k1bnktem9pZzB2SW5rdHJXY1k0d3ZaWDl3R1pBM3RkRVZxWDlwUWROSzVyNEdWeDRzRnlnOFhRb3JGU2x3cU1LbDdOLXd5bldGdjJndk1RY2ZwTjltQXFRUQ?oc=5","date":"2020-09-30","type":"deal","source":"Fierce Biotech","summary":"Pfizer funnels $200M into CStone, licenses late-stage cancer med in China - Fierce Biotech","headline":"Pfizer funnels $200M into CStone, licenses late-stage cancer med in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNaUVCeEotTlFEMGFRaURBd0FxaEJBOHUzOXRsTWtYRlNZYjVSV3NWQ3JkV1c0OGdFb29DbC1QeHlvNm1vbjNVWFVZc2czRFo0c0QtYnhhX21KUmlIU09XR3F5ejhxLTMzMzJjWGFfVkJsdGVHMnZSVXB0b2NFTGJ6VnBXVGlERUFTNnpHMWlyQ1pDQm1DczRSTEpneGVDLXNzYm9rWVZWWWdwWWZVVnBBOUZiQThkTlpQTHNYRHZSWFZMNko2ZTlCZ0xja1dIMEltZS1FWWc3dDJpMHJCQnFya01VekVTU1J5LTNLZElnTnNsOW5XMGpzQXplREdYSDh0V1NDVTlHNDZpZHhMV2RSSHN1clpsX2RHZTRCcVhPM0NaYlk0MkNhZmFGeWdwbG4tTFl5Vm5ySHU1N1JwaGFjUXlma2JtZ0FVUXE3NGpWVEpkYTFMMWc?oc=5","date":"2018-06-04","type":"deal","source":"PR Newswire","summary":"Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China - PR Newswire","headline":"Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Com","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}